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estimated from 2006-2012 for all branded and generic monotherapy formulations 
of lisinopril, hydrochlorothiazide, metformin, and levothyroxine. Claims were con-
sidered GDDP-filled if the following criteria were met: the only recorded price paid 
was patient out-of-pocket, and the quantity dispensed and out-of-pocket price-
paid matched published GDDP pharmacy lists, including Walmart, Walgreens, CVS, 
RiteAid, and Kroger. Results: In 2006, the percentage of GDDP-filled prescriptions 
was low: 8.1% (N= 4,472,797) of hydrochlorothiazide, 4.0% (N= 3,880,992) of levo-
thyroxine, 0.01% (N= 4,008) of metformin, and 0.0% of lisinopril. This increased in 
2008, to 2.4% (N= 1,676,928) for metformin, 8.0% (N= 7,107,840) for lisinopril, 16.8% 
(N= 9,024,532) for hydrochlorothiazide, and 18.9% (N= 13,035,972) for levothyroxine. 
In 2009, all medications had a GDDP-filled rate around 20% or greater. The high-
est percentages were seen in 2010: 22.5% (N= 12,033,009) of hydrochlorothiazide, 
25.1% (N= 27,033,234) of levothyroxine, 25.5% (N= 17,593,051) of metformin, and 
29.6% (N= 30,115,329) of lisinopril. By 2012 this decreased, and 19.6% (N= 9,715,614) 
of hydrochlorothiazide, 20.3% (N= 20,813,050) of lisinopril, 22.1% (N= 21,425,226) of 
levothyroxine, and 23.2% (N= 17,842,540) of metformin prescriptions were GDDP-
filled. ConClusions: By 2012, approximately 1 in 5 prescriptions for lisinopril, 
hydrochlorothiazide, metformin, and levothyroxine were filled using a GDDP. As 
they are cash-only, these prescriptions may not be processed via a pharmacy benefit 
manager, and therefore may be missing from insurance claims data.
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Timely Use Of ACe inhibiTOrs And Arbs AfTer newly diAgnOsed 
diAbeTes AmOng Older AdUlTs wiTh hyPerTensiOn in The U.s
Bogart M., Fang G., Annis I.
UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA
objeCtives: ACE inhibitors and ARBs are the cornerstone of therapy for patients 
with hypertension and type 2 diabetes. However, they have been shown to be under-
utilized in elderly patients at high risk for complications. The objectives of this 
study are to 1) assess earlier use of ACEIs/ARBs after incident diabetes diagnosis by 
race/ethnicity groups, and 2) assess whether the use of ACEIs/ARBs improves over 
time after diabetes diagnosis by race/ethnicity group. Methods: We identified fee-
for-service Medicare beneficiaries over the age of 65 with hypertension and newly 
diagnosed T2DM using data from CMS. Treatment use, baseline demographics, and 
other covariates were measured during the 12-month baseline period and the index 
date. Standardized differences were used to assess ACEI/ARB use and a marginal 
effects model with GEE was applied to investigate race/ethnicity differences in 
use rates. Results: 55.5% of 135,923 patients received ACEI/ARB therapy within 3 
months post-diabetes diagnosis (65.2% ACEIs, 38.5% ARBs). ACEI/ARB users within 3 
months after a diabetes diagnosis were younger and had fewer comorbidities, except 
for hyperlipidemia. Compared to non-users, ACEIs/ARBs users had more medica-
tion use. Among the racial/ethnic subgroups, Asians and Hispanics had the highest 
rate of use (59%), followed by Other (56%), White (55%), and Black (53%). Asians and 
Hispanics had 4% and 6% higher RR for use and Blacks had a 2% lower RR compared 
to Whites. Overall, rates of use over time decreased by 1% to 2%, except for a mild 
increase among Blacks (1% to 2%). However, subgroup analyses indicated that the 
decrease could be attributed to patients receiving ACEI/ARB therapy prior to diabetes 
diagnosis. Untreated patients showed an increase in use over time. ConClusions: 
Overall, ACEIs/ARBs are underutilized based on current treatment guidelines and 
use varies significantly across races/ethnicities. Future studies are needed to assess 
reasons for underuse of ACEIs/ARBs to promote better health outcomes.
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gAPs in sTATins Use AmOng Older AdUlTs wiTh new OnseT diAbeTes in 
The Us
Chung T.A., Bogart M., Annis I., Fang G.
UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA
objeCtives: The prevalence of statin use in older adults with new onset diabetes 
(T2DM), frequently presenting with co-morbidities and susceptible to poor out-
comes, has not been well characterized. The objective of this study was to exam-
ine and characterize the prevalence of statin use among Medicare patients newly 
diagnosed with diabetes, and to assess statins use gaps by age, gender, and race/
ethnicity as well as those with and without underlying cardiovascular disease 
(CVD). Methods: This was a retrospective cohort study using pharmacy and 
medical claims from CMS. Enrollees with a new T2DM diagnosis (index date) in 
2008, aged 65 years or older, continuously enrolled in Medicare Part A, B, and D, and 
who survived at least 90 days after the index date were included. The prevalence 
of statin use within 90 days of index date across age, gender, race/ethnicity, and 
baseline CVD status was assessed. Multivariable logistic regression was applied to 
investigate the effects of the independent variables. Results: An average statin 
usage rate of 46.3% was found in the 168,800 eligible patients included in the study. 
66,525 patients in the cohort had underlying co-morbid CVD and were more likely 
to receive statins than those without baseline CVD both before (OR= 1.62, 95% CI 
1.58-1.67) and after (OR= 1.23, 95% CI 1.17-1.28) adjusting for baseline treatment 
including statin medications, post- diagnosis. Significant disparities in statin use 
were found in gender, race/ethnicity, and age. Males were more likely than females 
to receive statins. Asians also higher statin usage compared to Caucasians, and 
those aged 65-74 were more likely use treatment compared to patients older than 
75. ConClusions: Statin treatment usage patterns vary significantly among newly 
diagnosed older adults with new onset diabetes.
PCV106
inflUenCe Of COsT shAring differenTiAls On TherAPeUTiC 
sUbsTiTUTiOn And mediCATiOn AdherenCe: The sTOry Of sTATins in 
2006
Li P., Schwartz S.J., Doshi J.A.
University of Pennsylvania, Philadelphia, PA, USA
objeCtives: The availability of enhanced Medicare Part D plans with generic-only 
coverage during the coverage gap (i.e. donut hole) and the genericization of pravas-
drugs in Croatia from 2000-2013 and to identify the rate of the generic drugs 
usage as well as the average price for 1 DDD. Methods: Data on the consump-
tion have been obtained from the database IMS (International Medical Statistics) 
for Croatia. According to the World Health Organization Collaborating Centre for 
Drugs Statistics Methodology annual volumes of drugs are presented in defined 
daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data 
are presented in Euros (€ ). Results: The total usage of Agents acting on RAS 
(C09 subgroup) in constantly increasing from 58,56 DDD/1000 inh/day in 2000. to 
199,88 DDD/1000 inh/day in 2013. In 14-year period, consumption in DDD/1000 
inh/day increased 241%, while the financial expenditure in same period increased 
74% (from 28,8 mil € in 2000 to 50,3 mil € in 2013), but achieved its maximum 
in 2008 (57,7 mil € ). The consumption share of generic Agents acting on RAS 
decreased from 90% in 2000 to 56% in 2006, then constantly increasing to 68% 
in 2013. ConClusions: Drugs prescription patterns among Agents acting on 
RAS have been changing during the 14-year period in Croatia. Impact of gener-
ics decreased until 2006. Because of introduction of new original drugs, but the 
national healthare policy promoting generics resulted in their increase of share 
up to 2013. Although the generic drugs usage in C09 subgroup is relatively high, it 
should be further supported and promoted.
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resUlTs Of An inTerVenTiOn in PresCriPTiOn Of COnVenTiOnAl releAse 
VerAPAmil in PATienTs wiTh hyPerTensiOn in COlOmbiA
Machado J., Machado-Duque M., Giraldo C.
Universidad TecnolÃ³gica de Pereira, Pereira, Colombia
objeCtives: Identify patients who were being treated for hypertension with conven-
tional release verapamil (CRV), notify the responsible of health care about cardiovas-
cular risk to which they are exposed and achieve a reduction in the number of patients 
who use it. Methods: A quasi-experimental prospective before and after study with-
out a control group was conducted in 7289 patients diagnosed with hypertension to 
be found in treatment with CRV, between October 1, 2012 and December 31, 2012 in 
8 Colombian cities from a database for dispensing medicines. Socio-demographic 
and pharmacological variables were evaluated. A total of 108 educational interven-
tions were performed for those responsible for health care, and evaluated within 
three months the proportion of suspension of the prescriptions of CRV. Multivariate 
analysis was performed using SPSS 22.0. Results: The mean age of patients was 
67.9±11.8 years (range: 26-96 years). 70.6% were men. Was obtained that discontinue 
treatment with CRV a total of 1922 patients (26.3% of users), distributed as follows: 
1160 (60.4%) were the presentation of 120 mg, while 762 (39.6%) the 80 mg. The vari-
able being treated in the city of Medellín (OR: 17.6; 95% CI: 11.949 to 25.924; p < 0.001) 
was associated statistically significant with change of CRV by another antihyperten-
sive. ConClusions: We found relative moderate adherence to recommendations 
about the proper use of CRV in hypertensive patients. Must be reinforced intervention 
programs that reduce inappropriate prescribing of potential risks to patients of insur-
ance companies and cities where the change was not achieved.
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drUg Use AmOng seniOrs On PUbliC drUg PrOgrAms in CAnAdA, 2012
Proulx J.
CIHI, Ottawa, ON, Canada
objeCtives: This analysis provides an in-depth look at the number and types of 
drugs used by seniors, and compares drug use among seniors living in long-term 
care (LTC) facilities and those living in the community. Methods: Data from the 
National Prescription Drug Utilization Information System (NPDUIS) Database, 
housed at CIHI, as submitted by eight Provincial drug programs and one Federal 
drug program in Canada, including drug claims for approximately 70% of Canadian 
seniors. Results: In 2012, nearly two-thirds (65.9%) of seniors had claims for 5 or 
more drug classes, and more than one-quarter (27.2%) of seniors had claims for 10 
or more drug classes. The proportion of seniors age 85 and older with claims for 10 
or more drug classes (39.3%) was double that of seniors age 65 to 74 (20.0%). Six of 
the 10 drug classes most commonly used by seniors were cardiovascular-related. 
The most commonly used drug class was statins, which are used by almost half 
of seniors (46.6%). More than one-third of seniors (38.9%) had claims for a drug on 
the Beers list—a list of drugs identified as potentially inappropriate to prescribe 
to seniors. More than half of seniors living in LTC facilities were using 10 or more 
different drug classes (60.9%), more than double the proportion among seniors liv-
ing in the community (26.1%). In LTC facilities benzodiazepine use was double the 
rate, antidepressant use triple the rate and antipsychotic use nine times the rate 
among seniors living in the community. ConClusions: Findings suggest a high 
proportion of seniors, particularly those living in LTC facilities may be at risk for 
drug interactions and other adverse events due to the number of medications they 
are taking. This illustrates the importance of medication management strategies for 
seniors, and the need for communication between health care providers regarding 
seniors’ drug regimens.
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generiC drUg disCOUnT PrOgrAms And Their POTenTiAl imPACT On The 
COmPleTeness Of PhArmACy ClAims dATA
Thompson J.A., Kelton C.M., Heaton P.C.
University of Cincinnati, Cincinnati, OH, USA
objeCtives: Generic Drug Discount Programs (GDDPs), introduced in 2006 and 
offered by the majority of retail pharmacies nationwide, offer many commonly 
used medications at low out-of-pocket prices. The objective of this study was to 
estimate the proportion of prescription claims filled using a GDDP for four com-
monly used medications. Methods: The Medical Expenditure Panel Survey annual 
prescribed medicines event file, a nationally representative sample that contains 
detailed drug information including payments made by private insurance, Medicaid/
Medicare, out-of-pocket, and other sources, was used for this study. Annual prescrip-
tion claim records, including new fills and refills of any quantity dispensed, were 
A148  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
tively. ConClusions: Hospitalizations for patients with HF are costly. On average 
hospitalizations due to worsening HF could range from $23,800 to $48,500 depending 
on the type of coverage. The costs of hospitalizations were higher in patients with 
commercial insurance when compared to Medicare advantage patients.
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CUrrenT resOUrCe UTilizATiOn PATTerns in mediCAre benefiCiAries 
diAgnOsed wiTh heArT fAilUre
Patel H.1, Sharma P.2, Maya J.1, Kilgore M.2, Kielhorn A.1
1Amgen, Thousand Oaks, CA, USA, 2Univeristy of Alabama at Birmingham, Birmingham, AL, 
USA
objeCtives: To estimate annual hospitalization rate and associated direct costs 
for Medicare beneficiaries with heart failure (HF). Methods: A 5% (n=3,493,434) 
national sample of Medicare beneficiaries was used to identify individuals with 
first observed primary inpatient claim for HF (ICD-9: 428.xx) between 07/01/2005 
and 12/31/2011. Patients having HF diagnoses in the 6 months prior to first observed 
claim were excluded. Patient demographics, use of HF medications and medical 
devices were reported. Annual hospitalization rate and associated total costs (the 
Centers for Medicare and Medicaid Services payment, as well as patient out-of-
pocket costs) were calculated. In order to account for varying lengths of follow-up, 
a per patient-year estimation method was used to calculate the cumulative rate 
of hospitalizations. Cumulative hospitalization rates and associated costs were 
estimated for all-cause hospitalizations, cardiovascular (CV) hospitalizations and 
HF-related hospitalizations. Results: A total of 63,678 patients met the study cri-
teria. Mean age was 82 years and 61% of patients were women. Among patients 
with part D coverage (n=35,788), 64.6% of patients used β blockers. On average, 
patients were hospitalized 2.19 times per patient-year for all-cause. Patients were 
hospitalized on average 1.02 times per patient-year for HF- and 1.30 times per 
patient-year for CV-related hospitalization. The costs associated with first observed 
all-cause hospitalization were $14,500, for CV-related hospitalization was $17,300 
and for HF-related hospitalization were approximately $16,000. ConClusions: 
CONCLUSIONS: Patients with HF who have been hospitalized had frequent subse-
quent hospitalizations. On an average, these individuals experienced 2 all-cause 
hospitalizations per year, one of them being due to worsening of HF. These hos-
pitalizations were costly, with costs ranging from $14,000 to $17,300 per episode.
PCV110
bAseline demOgrAPhiCs And CliniCAl ChArACTerisTiCs AssOCiATed 
wiTh heAlThCAre COsTs AmOng PATienTs wiTh ATherOsClerOTiC 
CArdiOVAsCUlAr diseAse
Power T.P.1, Ke X.2, Zhao Z.3, Bonine N.2, Cziraky M.J.2, Grabner M.2, Barron J.4, Quimbo R.2, 
Wertz D.2, Flickinger D.M.3, Vangerow B.3, Toth P.P.5
1AIM Specialty Health, Chicago, IL, USA, 2HealthCore Inc., Wilmington, DE, USA, 3Eli Lilly and 
Company, Indianapolis, IN, USA, 4HealthCore, Inc, Wilmington, DE, USA, 5CGH Medical Center, 
Sterling, IL, USA
objeCtives: To identify baseline demographics and clinical characteristics asso-
ciated with healthcare costs among patients with atherosclerotic cardiovascular 
disease (ASCVD). Methods: This retrospective cohort study identified newly 
diagnosed ASCVD patients aged ≥ 18 years using claims data from the HealthCore 
Integrated Research Database (HIRDSM) between 1/1/07 and 11/30/12 (index 
date= first ASCVD diagnosis date). Patients had both ≥ 12 month pre- and post-
index insurance enrollment, valid baseline lipid panel values, and no baseline lipid 
lowering medication use. Costs were adjusted to 2013 U.S. dollar values. Bivariate 
analyses and generalized linear models with gamma distribution and log link were 
used to examine baseline factors associated with 12 month follow-up all-cause and 
ASCVD-related healthcare costs. Results: In the regression model for all-cause 
healthcare costs (N= 26,388), older age, plan region including South and West (vs. 
Midwest), higher Quan-Charlson Comorbidity Index, index acute coronary syndrome 
(ACS), ischemic stroke or transient ischemic attack, baseline depression, pain, obe-
sity, and chronic kidney disease, baseline use of antihypertensive agents, antidia-
betic medications, and digoxin, and higher baseline all-cause healthcare costs were 
positively associated with follow-up all-cause healthcare costs (p< 0.05). In addi-
tion, female, Northeast plan (vs. Midwest), Health Maintenance Organization (vs. 
Preferred Provider Organization), Medicare Advantage plans, index coronary heart 
disease (except for ACS) or peripheral artery disease, baseline dyslipidemia, and 
baseline goal attainment of low-density lipoprotein cholesterol (< 100 mg/dL), high-
density lipoprotein cholesterol ( > 40/50 mg/dL for males and females respectively), 
triglycerides (< 150 mg/dL), and total cholesterol level (< 200 mg/dL) were negatively 
associated with follow-up all-cause healthcare costs (p< 0.05). Similar findings 
were reported for ASCVD-related healthcare costs (N= 26,376). ConClusions: As 
expected, age, gender, baseline comorbid conditions, baseline use of specific medi-
cations, baseline lipid profiles, and more severe index ASCVD were significantly 
associated with all-cause and ASCVD-related healthcare costs. Geographic location 
and health insurance type also played a significant role in healthcare costs among 
ASCVD patients.
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AnnUAl hOsPiTAlizATiOn freqUenCy fOr PATienTs wiTh heArT fAilUre 
- A COmPArisOn beTween COmmerCiAl And mediCAre AdVAnTAge 
POPUlATiOn
Patel H.1, Maya J.1, Song R.2, Henk H.J.2, Kielhorn A.1
1Amgen, Thousand Oaks, CA, USA, 2Optum, Eden Prairie, MN, USA
objeCtives: To estimate the cumulative annual hospitalization rate for patients 
with heart failure (HF). Methods: A retrospective analysis was undertaken using a 
large US claims database, the Optum Research Database. A per patient-year estima-
tion method was used to calculate a cumulative rate of hospitalization to account for 
varying lengths of follow-up. Patients ≥ 18 years, with a first observed inpatient heart 
failure claim (ICD-9: 428.xx; in primary position) between 01/01/08 and 06/30/13 were 
included. Patients having an inpatient claim for HF in the 2 months prior to the first 
tatin and simvastatin in early 2006, respectively, created a unique opportunity to 
examine how patient cost-sharing differentials for brand-name and generic drugs 
impact therapeutic substitution and medication adherence with statins. Methods: 
Using the 2006 5% Medicare files we identified continuous fee-for-service Part D 
covered patients with hyperlipidemia (ICD-9-CM 272.0-272.4) using the brand-
name statins (atorvastatin or rosuvastatin) between 1/1/2006 and 3/31/2006. The 
quasi-experimental study examined changes in outcomes across the pre- (prior to 
coverage gap) and post- (during coverage gap) periods for non-low income subsidy 
(non-LIS) patients with generic-only coverage in gap who faced substantial increases 
in brand-name statin cost sharing ($28 to $82 per 30-day supply) but no changes in 
generic cost-sharing from the pre- to post-period compared to a control group of 
LIS patients who faced no changes in brand-name ($3) or generic ($1) cost-sharing 
in the pre- and post-periods. The two groups were propensity-score matched on 
sociodemographics and clinical characteristics. Difference-in-difference regressions 
were used to examine impact on use of brand-name statins, generic statins, and 
overall any statin use. In addition, overall adherence (PDC> 0.80) to and discontinua-
tion (30-day gap) of statins was also examined. Results: Compared to LIS patients, 
non-LIS patients had a larger decline in brand-name statin use (-0.24 30-day-sup-
ply/month, p< 0.001), smaller increase in generic statin use (+0.06 30-day-supply/
month, p< 0.001), and hence, an overall drop in any statin use (-0.18 30-day-supply/
month, p< 0.001). Correspondingly, a decrease in adherence (OR: 0.81,p< 0.001) and 
increase in discontinuation (OR: 1.62,p< 0.001) on any statins was observed in non-
LIS patients relative to LIS patients. ConClusions: A substantial brand/generic 
cost-sharing differential was associated with therapeutic substitution of brand-
name statins with generic statins; however, it also resulted in declines in adherence 
and increases in discontinuation of statins.
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direCT mediCAl COsT COmPArisOn beTween PATienTs reCeiVing 
CAngrelOr And ClOPidOgrel dUring PerCUTAneOUs COrOnAry 
inTerVenTiOn: ChAmPiOn PhOenix eCOnOmiC sUb-sTUdy resUlTs
Nicholson G.1, Cyr P.1, Fan W.2, Plent S.2
1ICON Plc, Dublin, Ireland, 2The Medicines Company, Parsippany, NJ, USA
objeCtives: Intracoronary atherothrombosis complicates percutaneous coronary 
intervention (PCI). Cangrelor, a novel, intravenous P2Y12 inhibitor reduced the risk 
of death, MI, ischemia-driven revascularization and stent thrombosis at 48 hours 
by 22% compared to clopidogrel in the CHAMPION PHOENIX Trial. An economic 
sub-study was designed, from the perspective of the US healthcare system, to 
determine the direct medical costs during index hospitalization among cangrelor 
vs. clopidogrel patients and the subgroup receiving bivalirudin as antithrombin 
therapy. Methods: Hospital bills were collected from participating US sites in the 
CHAMPION PHOENIX trial. Hospital costs were determined by multiplying itemized 
hospital charges and the cost-center specific cost-to-charge ratios obtained from 
hospital’s Medicare Cost Report (MCR). A model predicting in-hospital costs was 
developed by utilizing multivariate imputation by chained equations (MICE) meth-
odology. The costs were imputed for patients where clinical but not economic data 
were available. After imputation, the index hospital costs from entire US population 
were compared between treatment groups. Results: Thirty-eight US sites were 
invited and 22 participated. One site was excluded due to incomplete MCR. Hospital 
bills from 1117 patients (27.3% of 4,097 CHAMPION PHOENIX US population) were 
utilized. Patients’ baseline characteristics and complications were similar to the 
rest of US population. After the MICE imputation, the index hospitalization costs of 
patients receiving cangrelor and clopidogrel were not statistically different ($11,755 
cangrelor vs. $11,914 clopidogrel, P= NS, difference= $159) even when bivalirudin as 
the anticoagulant was utilized ($12,941 cangrelor/bivalirudin vs. $13,216 clopidogrel/
bivalirudin, P= NS, difference= $275). Data also shows a numerical saving of $109 
for catheterization laboratory costs among cangrelor-treated patients ($9,030 vs. 
$9,139, P= NS) with similar results among bivalirudin subgroup. ConClusions: This 
analysis reveals similar direct medical costs, from the perspective of the US health-
care system, for cangrelor patients (with or without bivalirudin) during the index 
hospitalization and catheterization laboratory in the CHAMPION PHOENIX trial.
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hOsPiTAlizATiOn COsTs fOr PATienTs wiTh heArT fAilUre Using ClAims 
dATAbAse Â€ “ A COmPArisOn beTween COmmerCiAl And mediCAre 
AdVAnTAge POPUlATiOn
Kielhorn A.1, Maya J.1, Song R.2, Henk H.J.2, Patel H.1
1Amgen, Thousand Oaks, CA, USA, 2Optum, Eden Prairie, MN, USA
objeCtives: To estimate the mean cost per episode of hospitalization for patients 
with heart failure (HF). Methods: A retrospective analysis was undertaken using a 
large US claims database, the Optum Research Database. Adult patients with a first 
observed inpatient HF claim (ICD-9: 428.xx; in primary position) between 01/01/08 and 
06/30/13 were included. Patients having an inpatient claim for HF in the 2 months 
prior to the first observed claim were excluded. Direct costs included the amount 
paid by insurance plan, co-ordination of benefits and patient out-of-pocket costs. 
Cumulative hospitalization rates were estimated for all HF-related hospitaliza-
tions, cardiovascular (CV) hospitalizations and all-cause hospitalizations, within 
the study period. Results were further categorized by types of insurance, specifi-
cally, commercial and Medicare advantage. Results: A total of 85,938 patients met 
the study criteria of which 68.3% (n= 58,732) had Medicare Advantage coverage and 
31.7% (n= 27,206) had commercial insurance. The mean age was 63 years for patients 
with commercial insurance and 77 years for those with Medicare advantage. For 
the total population (commercial + Medicare advantage), the mean direct costs 
were approximately $30,900 for a HF- related hospitalization, $30,400 for CV-related 
hospitalization, and $25,400 for an all-cause hospitalization. For patients with com-
mercial insurance, the mean costs were approximately $48,500, $47,700 and, $40,000 
for a HF-related, CV-related, and all-cause hospitalization episode, respectively. For 
patients with Medicare advantage, the mean costs were approximately $23,800, 
$23,400 and $19,600 for HF-related, CV-related, and all-cause hospitalizations, respec-
